ABI's Mass Spec Tools Will Play Role In BG Medicine, FDA's Hepatotox Biomarker Project | GenomeWeb
NEW YORK (GenomeWeb News) — The US Food and Drug Administration has approved the first phase of a BG Medicine and National Center for Toxicological Research project to develop biomarkers for liver toxicity, BG Medicine said today.
 
The company also said it will use mass spectrometry technology made by Applied Biosystems, and has named seven pharmaceutical companies that will participate in the project.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.